This review highlights the emergence and specific indications of potent new antiarrhythmic drugs for the management of various cardiac arrhythmias.
Answers are grounded in this paper and cite their sources.
May expand options for specific arrhythmias; leaves open need for randomized confirmation of efficacy and safety.
The new and potent antiarrhythmic drugs herald an exciting era in the treatment of cardiac arrhythmias. Encainide, tocainide, and mexiletine are effective in treating acute and chronic ventricular arrhythmias. Verapamil promises to be the drug of choice for paroxysmal supraventricular tachycardia. Acetubolol provides the advantages of selective beta receptor blockade and has minimal influence on pulmonary function. Aprindine and amiodarone block conduction in accessory pathways and are very suitable for treating tachycardias associated with Wolff-Parkinson-White syndrome. Ethmozin is a phenothiazine derivative with potent antiarrhythmic effects. Many of these new agents are being used with striking success abroad and at specialized treatment centers for experimental research in the United States.
No takes yet. Share an insight, caveat, or question.
Benchimol et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: